The same macro factors affecting the equities market, such as tariffs, geopolitical factors, and a changing interest rate policy are also affecting the fixed income markets. With that, there's never been a better time to access active fixed income strategies that help advisors and investors navigate the murky macro environment. Vanguard has nine active ETF options that can work for any investor, depending on their specific fixed income goals. It's been a memorable year for active ETFs overall with a record ...

While VOO provides broad market exposure, MGK targets only mega-cap stocks. Here's how they stack up.The Vanguard Mega Cap Growth ETF (MGK +0.78%) and the Vanguard S&P 500 ETF (VOO +0.36%) differ most in their sector concentrations, dividend yields, and long-term risk-return profiles.Both MGK and VOO are Vanguard funds, but MGK zeroes in on the largest U.S. growth stocks, while VOO tracks the full S&P 500 -- offering exposure to a broader array of top U.S. companies. This comparison spotlights key differenc ...

Core Viewpoint - Merck's growth is heavily reliant on Keytruda, which poses risks as competition increases and patent expiration approaches [1][3][9] Sales Performance - Keytruda's sales surged 72% from $17 billion in 2021 to $29 billion in 2022, constituting 46% of Merck's total revenues [2][9] - The drug has been the primary driver of Merck's double-digit revenue growth over the past three years [2] Patent Expiration and Competition - Keytruda's U.S. market exclusivity is set to end in 2028, leading to anticipated biosimilar competition [3][4] - Sales are projected to peak at around $36 billion by 2028, with potential declines to $20 billion or below in the following years [3][5] Impact of Biosimilars - Historical examples show that sales can drop sharply with the entry of biosimilars, as seen with AbbVie's Humira and Roche's Herceptin [4] - Humira's sales fell nearly 60% from $21 billion in 2022 to under $9 billion, illustrating the disruptive nature of biosimilar competition [4] Future Growth Challenges - Merck is unlikely to maintain sales growth as Keytruda's sales are expected to decline significantly [5][6] - The company must find new revenue streams within the next three years to avoid slower or falling sales [7][9] Investment Implications - The situation highlights the need for a diversified investment portfolio to manage concentrated risks associated with reliance on a single product [10] - Merck's dependency on Keytruda represents both a current strength and a significant vulnerability for future growth [9][10]